Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Cencora moves billions of dollars in branded, generic, and specialty drugs—and how much it sets aside for opioid litigation—means combing through dense regulatory documents. Cencora SEC filings explained simply is what most investors search for when a new disclosure lands. Stock Titan solves that problem by turning every freshly posted exhibit, footnote, and schedule into plain-English insights within minutes.
Our platform reads each Cencora annual report 10-K simplified, compares segment margins, and highlights cash-flow drivers hidden in accounting tables. You’ll also receive instant alerts the moment a director files Cencora Form 4 insider transactions real-time. Key features include:
- AI-powered summaries that clarify complex wording and accounting changes
- Real-time push notifications for new 10-K, 10-Q, 8-K, and Cencora insider trading Form 4 transactions
- Side-by-side visuals that streamline Cencora earnings report filing analysis
Whether you’re waiting for the next Cencora quarterly earnings report 10-Q filing, researching Cencora executive stock transactions Form 4, or need Cencora 8-K material events explained after an unexpected acquisition, everything is organized in one place. We even map the pages inside the Cencora proxy statement executive compensation section, so pay packages are only a click away. Stop downloading PDFs; start understanding Cencora SEC documents with AI that surfaces the metrics that matter.
Steven H. Collis, Executive Chairman and Director of Cencora, Inc. (COR), reported option exercise and open-market sales on 08/19/2025. He exercised 12,579 non-qualified stock options with an exercise price of $86.09, acquiring 12,579 shares underlying those options. The exercise increased his direct holdings to 322,491.665 shares. On the same date he sold 14,579 shares at $289.98 per share, leaving 307,912.665 shares after the transactions. The sale was effected under a Rule 10b5-1 trading plan adopted on 11/25/2024. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Robert P. Mauch, President & CEO and Director of Cencora, Inc. (COR), reported option exercises and open-market sales on 08/18/2025. He exercised 3,225 non-qualified stock options with an exercise price of $86.09 under a grant that vests in four prior annual installments, and those options produced 3,225 shares recorded as acquired. The same day he sold 4,968 shares at $293.53 per share pursuant to a Rule 10b5-1 trading plan adopted 11/15/2024. After these transactions he beneficially owned 40,608 shares and held 22,577 derivative securities (options) reported as direct ownership.
Cencora, Inc. (COR) Form 144 shows proposed and recent insider sales of common stock by Steven Collis. The filing notifies a brokered proposed sale of 14,579 shares with an aggregate market value of $4,227,618.42 scheduled for 08/19/2025 on the NYSE through Fidelity Brokerage Services. The filing also discloses the acquisition history for the shares to be sold: 2,000 shares from restricted stock vesting on 09/30/2023 (compensation) and 12,579 shares from an option exercise dated 08/19/2025 (cash).
Separately, three insider sales by Steven Collis during the past three months are reported: 14,578 shares on 05/20/2025 for $4,283,599.52, 14,579 shares on 06/24/2025 for $4,266,106.98, and 14,578 shares on 07/22/2025 for $4,265,100.54. The filing includes the seller's representation about lack of undisclosed material information and a signature notice regarding legal penalties for misstatement.
Cencora, Inc. insider sale notice under Rule 144: The filing shows a proposed sale of 4,968 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $1,458,257.04 and an approximate sale date of 08/18/2025. The shares were acquired partly through restricted stock vesting on 09/30/2023 (1,743 shares) as compensation and partly via option exercise on 08/18/2025 (3,225 shares) related to an option granted 11/13/2019 and paid in cash. The filer also disclosed three prior monthly sales of similar sizes in May, June and July 2025 totaling 14,906 shares with gross proceeds of approximately $4.38 million. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Q3 FY25 results: Revenue rose 8.7 % YoY to $80.7 B; gross profit +20 % to $2.9 B; operating income +29 % to $867.7 M; diluted EPS climbed 45 % to $3.52. For the nine-month period, sales reached $237.6 B (+10.6 %) and net income was $1.89 B (+25.8 %).
Cash & liquidity: Operating cash flow dropped to $0.74 B (vs $2.48 B last year) as working-capital swings outweighed earnings growth. Cash & equivalents fell to $2.23 B.
Major transaction: Closed the $5.7 B acquisition of 85 % of Retina Consultants of America, adding $1.4 B revenue and $4.8 B goodwill. Financing included $4.5 B USD notes, €1.0 B notes and a $1.5 B term loan, lifting long-term debt to $8.0 B (from $3.8 B).
Balance sheet: Total assets $74.0 B; goodwill $14.3 B. Accrued opioid-related litigation liability steady at $4.28 B. Share buy-backs of $435 M reduced outstanding shares to 193.9 M.
Segments: U.S. Healthcare Solutions delivered $72.9 B revenue (+8.5 %); International $7.79 B (+10.5 %). FX gains drove $367 M other comprehensive income.
Key watch-points: leverage expansion, potential PharmaLex goodwill impairment ($724 M), rising interest expense and continuing opioid/DEA litigation.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
